A recent clinical trial (ClinicalTrials.gov Identifier: NCT02034981) has been initiated to assess the efficacy of crizotinib in cancer patients identified with amplication of crizotinib target genes—anaplastic lymphoma kinase (ALK), MET or ROS proto-oncogene 1 (ROS1) positive (Table 1). The gene discussed is ALK; the disease is cancer.